Clinical stage biotechnology company AdAlta Limited (ASX:1AD) reports that the first cohort of healthy volunteers has received the first of three doses in Part B of the Phase I clinical trial of AD-214.
VP Clinical Product Development. Dr Claudia Gregorio-King, said eight participants have received 5 mg/kg AD-214 or placebo with no reported dose limiting adverse events.
We are pleased to have progressed into the multiple dose part of our initial clinical evaluation of AD-214,” Dr Gregorio-King said.
“The excellent safety profile and high receptor occupancy observed in the single dose Part A of our study facilitated rapid ethics approval of Part B of the Phase I programme.
“We also remain on track to begin our multi-dose study in interstitial lung disease patients in the third quarter of 2021.
“We continue to express our gratitude to the volunteers who have agreed to participate in our study and help advance a potential new therapy for patients battling idiopathic pulmonary fibrosis and other interstitial lung diseases.”
Completion of Part B of the Phase I study is expected by the end of 2021 and is anticipated to provide the data necessary to support Phase II clinical trial applications in 2022.
AdAlta Limited is using its proprietary i-body technology platform to generate a promising new class of medicines with the potential to treat some of today’s most challenging diseases.
The company’s lead asset, called AD-214, is a first-in-class product being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF), other human fibrotic diseases and potentially cancers, for which current therapies are sub- optimal and there is a high unmet medical need. AD-214 is well progressed in Phase I clinical trials.
AD-214 is being developed for the treatment of IPF and other human fibrotic diseases and potentially cancers, for which current therapies are sub-optimal and there is a high unmet medical need. AD-214 targets a GPCR called CXCR4 and has been specifically engineered to include features making it suitable for chronic use in fibrosis. It is the only agent against CXCR4 being developed for fibrotic diseases, giving it first-in-class status.
AD-214 has demonstrated efficacy in animal models of IPF and kidney fibrosis and studies in eye fibrosis and metastatic cancer are underway.
In Phase I clinical trials, AD-214 is well tolerated in single doses in healthy volunteers and demonstrates high and sustained duration of CXCR4 receptor occupancy. Repeat dose studies in healthy volunteers have commenced. Safety and biodistribution (PET imaging) studies in IPF and ILD patients are in advanced planning.
